Acupuncture has also been employed to relieve pain and improve movement in people with osteoarthritis (OA) of the knee. In the largest clinical study of acupuncture reported to date, Berman et al (2004) studied 570 patients with an average age of 65 who had OA of the knee. Subjects were randomly assigned to receive one of three treatments for 26 weeks, in addition to standard care such as anti-inflammatory medications and pain relievers: (i) 190 received acupuncture, (ii) 191 underwent sham acupuncture and (iii) 189 participants attended 6, 2-hour group sessions over 12 weeks based on the Arthritis Foundation's Arthritis Self-Help Course. Patients' progress was assessed at 4, 8, 14, and 26 weeks. At week 8, patients receiving acupuncture began showing a significant increase in function and by week 14 a significant decrease in pain, compared with the sham and control groups. Overall those who received acupuncture had a 40 % decrease in pain and a nearly 40 % improvement in function compared to baseline assessments. The authors concluded that acupuncture seems to provide improvement in function and pain relief as an adjunctive therapy for OA of the knee when compared with credible sham acupuncture and education control groups. This finding is in agreement with the recent observations of Vas et al (2004), Tukmachi et al (2004), as well as that of Stener-Victorin et al (2004).
Isabelle Rapin ... finds Dr. Baron-Cohen's theory "provocative" but adds that "it does not account for some of the many neurological features of the disorder, like the motor symptoms [such as repetitive movements and clumsiness], the sleep problems or the seizures." Others worry that the term "extreme male brain" could be misinterpreted. Males are commonly associated with "qualities such as aggression," says Helen Tager-Flusberg ... "What's dangerous is that's the inference people will make: Oh, these are extreme males." 
Cystic fibrosis is a rare disease that affects about 30,000 people in the United is indicated for patients aged 2 and older who have one mutation in the CFTR gene that is responsive to drug treatment based on clinical and/or in vitro (laboratory) data. The expanded indication will affect another 3 percent of the cystic fibrosis population, impacting approximately 900 patients. Kalydeco serves as an example of how successful patient-focused drug development can provide greater understanding about a disease. For example, the Cystic Fibrosis Foundation maintains a 28,000-patient registry, including genetic data, which it makes available for research.